Advertisement

Current Urology Reports

, 20:66 | Cite as

The Microbiome and Prostate Cancer Risk

  • Karen M. Wheeler
  • Michael A. LissEmail author
Prostate Cancer (S Prasad, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Prostate Cancer

Abstract

Purpose of the Review

There is an abundance of evidence that the human microbiome plays an important and nuanced role in controlling human metabolism, immunity, and cancer. Herein we aim to review the most current research looking at prostate cancer and its link with the gut and genitourinary microbiome.

Recent Findings Summary

There is now a host of evidence for a unique genitourinary (GU) microbiome. The prostate microbiota, to include viral, bacterial, fungal, and parasitic contributions, as assessed from formalin-fixed tissue is described nicely in the study by Banerjee et al. Further hierarchical analysis by this group found a unique microbiome signature for higher Gleason score cancers and validation PCR studies noted a marked number of viral genomic insertions into host DNA. Shretha et al. also recently established unique GU microbiomes in patients with prostate cancer or benign prostate pathology based on urine samples. The gut microbiome likely also has an indirect but significant role in prostate cancer development and treatment. Liss et al. and Golombos et al. found significant associations between specific gut microbiota and prostate cancer. Interestingly, the balance of inflammatory and anti-inflammatory bacterial lipopolysaccharides, production of bile salts, and metabolism of dietary fiber to short chain fatty acids all likely play important roles in creating systemic pro- or anti-carcinogenic states. In terms of prostate cancer treatment effects, Sfanos et al. noted a unique microbial signature in patients undergoing oral androgen deprivation therapy (ADT) as compared with prostate cancer patients not on ADT. Patients undergoing ADT also had enrichment of bacterial metabolic pathways promoting androgen synthesis. Together, these studies have identified a unique GU microbiome and linked both the GU microbiome and unique gut microbial signatures with prostate cancer and prostate cancer treatments. Whether this information can be used in cancer prevention, treatment, or diagnosis are areas of ongoing and active research.

Keywords

Prostate cancer Microbiota Gut microbiome Genitourinary microbiome 

Notes

Compliance with Ethical Standards

Conflict of Interest

Karen M. Wheeler and Michael A. Liss each declare no potential conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, et al. A human gut microbial gene catalog established by metagenomic sequencing. Nature. 2010;464:59.CrossRefGoogle Scholar
  2. 2.
    Cho I, Blaser MJ. The human microbiome: at the interface of health and disease. Nat Rev Gen. 2012;13:260.CrossRefGoogle Scholar
  3. 3.
    Lloyd-Price J, Abu-Ali G, Huttenhower C. The healthy human microbiome. Genome Med. 2016;8:51.CrossRefGoogle Scholar
  4. 4.
    Lee YK, Mazmanian SK. Has the microbiota played a critical role in the evolution of the adaptive immune system? Science. 2010;330:1768–73.CrossRefGoogle Scholar
  5. 5.
    Tang Z, Chen G, Hong Q, Huang S, Smith HM, Shah RD, et al. Multi-omic analysis of the microbiome and metabolome in healthy subjects reveals microbiome-dependent relationships between diet and metabolites. Front Genet. 2019;10:454.CrossRefGoogle Scholar
  6. 6.
    Benson AK, Kelly SA, Legge R, Ma F, Low SJ, Kim J, et al. Individuality in gut microbiota composition is a complex polygenic trait shaped by multiple environmental and host genetic factors. Proc Natl Acad Sci U S A. 2010;107:18933–18,938.CrossRefGoogle Scholar
  7. 7.
    Chen C, Huang X, Fang S, Yang H, He M, Zhao Y, et al. Contribution of host genetics to the variation of microbial composition of cecum lumen and feces in pigs. Front Microbiol. 2018;9:2626–6.Google Scholar
  8. 8.
    Davenport ER. Elucidating the role of the host genome in shaping microbiome composition. Gut Microbes. 2016;7:178–84.CrossRefGoogle Scholar
  9. 9.
    Konkol Y, Keskitalo A, Vuorikoski H, Pietila S, Elo LL, Munukka E, et al. Chronic nonbacterial prostate inflammation in a rat model is associated with changes of gut microbiota that can be modified with a galactoglucomannan-rich hemicellulose extract in the diet. BJU Int. 2019;123:899–908.CrossRefGoogle Scholar
  10. 10.
    David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature. 2014;505:559–63.CrossRefGoogle Scholar
  11. 11.
    Sethi V, Kurtom S, Tarique M, Lavania S, Malchiodi Z, Hellmund L, et al. Gut microbiota promotes tumor growth in mice by modulating immune response. Gastroenterology. 2018;155:33–37.e6.CrossRefGoogle Scholar
  12. 12.
    Capurso G, Lahner E. The interaction between smoking, alcohol and the gut microbiome. Best Pract Res Clin Gastroenterol. 2017;31:579–88.CrossRefGoogle Scholar
  13. 13.
    Merchant HA, Liu F, Gul MO, Basit AW. Age-mediated changes in the gastrointestinal tract. Int J Pharm. 2016;512:382–95.CrossRefGoogle Scholar
  14. 14.
    Wang J, Jia H. Metagenome-wide association studies: fine-mining the microbiome. Nat Rev Microbiol. 2016;14:508.CrossRefGoogle Scholar
  15. 15.
    Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357:539–45.CrossRefGoogle Scholar
  16. 16.
    Ishaq S, Nunn L. Helicobacter pylori and gastric cancer: a state of the art review. Gastroenterol Hepatol Bed Bench. 2015;8:S6–S14.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Schwabe RF, Jobin C. The microbiome and cancer. Nat Rev Cancer. 2013;13:800.CrossRefGoogle Scholar
  18. 18.
    Cheng M, Qian L, Shen G, Bian G, Xu T, Xu W, et al. Microbiota modulate tumoral immune surveillance in lung through a gammadeltaT17 immune cell-dependent mechanism. Cancer Res. 2014;74:4030–41.CrossRefGoogle Scholar
  19. 19.
    Boursi B, Mamtani R, Haynes K, Yang YX. Recurrent antibiotic exposure may promote cancer formation--another step in understanding the role of the human microbiota? Eur J Cancer. 2015;51:2655–64.CrossRefGoogle Scholar
  20. 20.
    McColl KE. Clinical practice. Helicobacter pylori infection. N Engl J Med. 2010;362:1597–604.CrossRefGoogle Scholar
  21. 21.
    Aragon IM, Herrera-Imbroda B, Queipo-Ortuno MI, Castillo E, Del Moral JS, Gomez-Millan J, et al. The urinary tract microbiome in health and disease. Eur Urol Focus. 2018;4:128–38.CrossRefGoogle Scholar
  22. 22.
    Bajic P, Van Kuiken ME, Burge BK, Kirshenbaum EJ, Joyce CJ, Wolfe AJ, et al. Male bladder microbiome relates to lower urinary tract symptoms. Eur Urol Focus. 2018.Google Scholar
  23. 23.
    Cavarretta I, Ferrarese R, Cazzaniga W, Saita D, Luciano R, Ceresola ER, et al. The microbiome of the prostate tumor microenvironment. Eur Urol. 2017;72:625–31.CrossRefGoogle Scholar
  24. 24.
    Feng Y, Ramnarine VR, Bell R, Volik S, Davicioni E, Hayes VM, et al. Metagenomic and metatranscriptomic analysis of human prostate microbiota from patients with prostate cancer. BMC Genomics. 2019;20:146–019-5457-z.Google Scholar
  25. 25.
    •• Banerjee S, Robertson ES, Alwine JC, Tian T, Wei Z, Feldman MD et al Microbiome signatures in prostate cancer. 2019. This article is important because it addresses the microbiome of the microbiome in prostate cancer microenvironment. Google Scholar
  26. 26.
    Namiki K, Goodison S, Porvasnik S, Allan RW, Iczkowski KA, Urbanek C, et al. Persistent exposure to Mycoplasma induces malignant transformation of human prostate cells. PLoS One. 2009;4:e6872.CrossRefGoogle Scholar
  27. 27.
    Miyake M, Ohnishi K, Hori S, Nakano A, Nakano R, Yano H, et al. Mycoplasma genitalium Infection and chronic inflammation in human prostate cancer: detection using prostatectomy and needle biopsy specimens. Cells. 2019;8.  https://doi.org/10.3390/cells8030212.CrossRefGoogle Scholar
  28. 28.
    Fehri LF, Mak TN, Laube B, Brinkmann V, Ogilvie LA, Mollenkopf H, et al. Prevalence of Propionibacterium acnes in diseased prostates and its inflammatory and transforming activity on prostate epithelial cells. Int J Med Microbiol. 2011;301:69–78.CrossRefGoogle Scholar
  29. 29.
    Chen Y, Wei J. Identification of pathogen signatures in prostate cancer using RNA-seq. PLoS One. 2015;10:e0128955.CrossRefGoogle Scholar
  30. 30.
    Javurek AB, Spollen WG, Ali AM, Johnson SA, Lubahn DB, Bivens NJ, et al. Discovery of a novel seminal fluid microbiome and influence of estrogen receptor alpha genetic status. Sci Rep. 2016;6:23027.CrossRefGoogle Scholar
  31. 31.
    De Spiegeleer B, Verbeke F, D’Hondt M, Hendrix A, Van De Wiele C, Burvenich C, et al. The quorum sensing peptides PhrG, CSP and EDF promote angiogenesis and invasion of breast cancer cells in vitro. PLoS One. 2015;10:e0119471.CrossRefGoogle Scholar
  32. 32.
    Minu S, Lualhati H, Katrin K, Britt WJ, Cobbs CS. High prevalence of human cytomegalovirus in prostatic intraepithelial neoplasia and prostatic carcinoma. J Urol. 2003;170:998–1002.CrossRefGoogle Scholar
  33. 33.
    Fioriti D, Videtta M, Mischitelli M, Degener AM, Russo G, Giordano A, et al. The human polyomavirus BK: Potential role in cancer. J Cell Physiol. 2005;204:402–6.CrossRefGoogle Scholar
  34. 34.
    Martinez-Fierro M, Leach RJ, Gomez-Guerra L, Garza-Guajardo R, Johnson-Pais T, Beuten J, et al. Identification of viral infections in the prostate and evaluation of their association with cancer. BMC Cancer. 2010;10:326–6.Google Scholar
  35. 35.
    Shrestha E, White JR, Yu S, Ibrahim K, Onur E, De Marzo AM, et al. Profiling the urinary microbiome in men with positive versus negative biopsies for prostate cancer. J Urol. 2018;199:161–71.CrossRefGoogle Scholar
  36. 36.
    Carabotti M, Scirocco A, Maselli MA, Severi C. The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems. Ann Gastroenterol. 2015;28:203–9.PubMedPubMedCentralGoogle Scholar
  37. 37.
    Sandrini S, Aldriwesh M, Alruways M, Freestone P. Microbial endocrinology: host-bacteria communication within the gut microbiome. J Endocrinol. 2015;225:R21–34.CrossRefGoogle Scholar
  38. 38.
    Vivarelli S, Salemi R, Candido S, Falzone L, Santagati M, Stefani S, et al. Gut microbiota and cancer: from pathogenesis to therapy. Cancers (Basel). 2019;11.  https://doi.org/10.3390/cancers11010038.CrossRefGoogle Scholar
  39. 39.
    Lazar V, Ditu L, Pircalabioru GG, Gheorghe I, Curutiu C, Holban AM, et al. Aspects of gut microbiota and immune system interactions in infectious diseases, immunopathology, and cancer. Front Immunol. 2018;9:1830.CrossRefGoogle Scholar
  40. 40.
    Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, et al. Commensal bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015;350:1084–9.CrossRefGoogle Scholar
  41. 41.
    Rao VP, Poutahidis T, Ge Z, Nambiar PR, Boussahmain C, Wang YY, et al. Innate immune inflammatory response against enteric bacteria Helicobacter hepaticus induces mammary adenocarcinoma in Mice. Cancer Res. 2006;66:7395–400.CrossRefGoogle Scholar
  42. 42.
    Poutahidis T, Cappelle K, Levkovich T, Lee C, Doulberis M, Ge Z, et al. Pathogenic intestinal bacteria enhance prostate cancer development via systemic activation of immune cells in mice. PLoS One. 2013;8:e73933.CrossRefGoogle Scholar
  43. 43.
    Gnauck A, Lentle RG, Kruger MC. The characteristics and function of bacterial lipopolysaccharides and their endotoxic potential in humans. Int Rev Immunol. 2016;35:189–218.CrossRefGoogle Scholar
  44. 44.
    Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56:1761–72.CrossRefGoogle Scholar
  45. 45.
    Jain S, Suklabaidya S, Das B, Raghav SK, Batra SK, Senapati S. TLR4 activation by lipopolysaccharide confers survival advantage to growth factor deprived prostate cancer cells. Prostate. 2015;75:1020–33.CrossRefGoogle Scholar
  46. 46.
    Shukla S, MacLennan GT, Fu P, Patel J, Marengo SR, Resnick MI, et al. Nuclear factor-kappaB/p65 (Rel A) is constitutively activated in human prostate adenocarcinoma and correlates with disease progression. Neoplasia. 2004;6:390–400.CrossRefGoogle Scholar
  47. 47.
    Vykhovanets EV, Shankar E, Vykhovanets OV, Shukla S, Gupta S. High-fat diet increases NF-κB signaling in the prostate of reporter mice. Prostate. 2011;71:147–56.CrossRefGoogle Scholar
  48. 48.
    d’Hennezel E, Abubucker S, Murphy LO, Cullen TW. Total lipopolysaccharide from the human gut microbiome silences toll-like receptor signaling. mSystems. 2017;2.  https://doi.org/10.1128/mSystems.00046-17 eCollection.
  49. 49.
    Vatanen T, Kostic AD, d’Hennezel E, Siljander H, Franzosa EA, Yassour M, et al. Variation in microbiome LPS immunogenicity contributes to autoimmunity in humans. Cell. 2016;165:842–53.CrossRefGoogle Scholar
  50. 50.
    EMM Quigley. Leaky gut - concept or clinical entity? Curr Opin Gastroenterol. 2016; 32.Google Scholar
  51. 51.
    Bäckhed F, Roswall J, Peng Y, Feng Q, Jia H, Kovatcheva-Datchary P, et al. Dynamics and stabilization of the human gut microbiome during the first year of life. Cell Host Microbe. 2015;17:690–703.CrossRefGoogle Scholar
  52. 52.
    Macpherson AJ, Harris NL. Interactions between commensal intestinal bacteria and the immune system. Nat Rev Immunol. 2004;4:478–85.CrossRefGoogle Scholar
  53. 53.
    Dobber R, Hertogh-Huijbregts A, Rozing J, Bottomly K, Nagelkerken L. The involvement of the intestinal microflora in the expansion of CD4+ T cells with a naive phenotype in the periphery. Dev Immunol. 1992;2:141–50.CrossRefGoogle Scholar
  54. 54.
    Ivanov II, Atarashi K, Manel N, Brodie EL, Shima T, Karaoz U, et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell. 2009;139:485–98.CrossRefGoogle Scholar
  55. 55.
    Pandiyan P, Bhaskaran N, Zou M, Schneider E, Jayaraman S, Huehn J. Microbiome dependent regulation of Tregs and Th17 cells in mucosa. Front Immunol. 2019;10:426.CrossRefGoogle Scholar
  56. 56.
    Campbell C, Dikiy S, Bhattarai SK, Chinen T, Matheis F, Calafiore M, et al. Extrathymically generated regulatory t cells establish a niche for intestinal border-dwelling bacteria and affect physiologic metabolite balance. Immunity. 2018;48:1245–1257.e9.CrossRefGoogle Scholar
  57. 57.
    O’Mahony C, Scully P, O’Mahony D, Murphy S, O’Brien F, Lyons A, et al. Commensal-induced regulatory T cells mediate protection against pathogen-stimulated NF-kappaB activation. PLoS Pathog. 2008;4:e1000112.CrossRefGoogle Scholar
  58. 58.
    Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermúdez-Humarán LG, Gratadoux J, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A. 2008;105:16731.CrossRefGoogle Scholar
  59. 59.
    Liss MA, White JR, Goros M, Gelfond J, Leach R, Johnson-Pais T, et al. Metabolic biosynthesis pathways identified from fecal microbiome associated with prostate cancer. Eur Urol. 2018;74:575–82.CrossRefGoogle Scholar
  60. 60.
    • Golombos DM, Ayangbesan A, O’Malley P, Lewicki P, Barlow L, Barbieri CE, et al. The role of gut microbiome in the pathogenesis of prostate cancer: a prospective, pilot study. Urology. 2018;111:122–8. This article is of importance because it identifies the enrichment of bacteroidetes in the feces of prostate cancer patients compared to men with BPH. CrossRefGoogle Scholar
  61. 61.
    Alanee S, El-Zawahry A, Dynda D, Dabaja A, McVary K, Karr M, et al. A prospective study to examine the association of the urinary and fecal microbiota with prostate cancer diagnosis after transrectal biopsy of the prostate using 16sRNA gene analysis. Prostate. 2019;79:81–7.CrossRefGoogle Scholar
  62. 62.
    Zheng X, Huang F, Zhao A, Lei S, Zhang Y, Xie G, et al. Bile acid is a significant host factor shaping the gut microbiome of diet-induced obese mice. BMC Biol. 2017;15:120–017–0462-7.CrossRefGoogle Scholar
  63. 63.
    Islam KB, Fukiya S, Hagio M, Fujii N, Ishizuka S, Ooka T, et al. Bile acid is a host factor that regulates the composition of the cecal microbiota in rats. Gastroenterology. 2011;141:1773–81.CrossRefGoogle Scholar
  64. 64.
    Ma Y, Brusselaers N. Maintenance use of aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs) and prostate cancer risk. Prostate Cancer Prostatic Dis. 2018;21:147–52.CrossRefGoogle Scholar
  65. 65.
    Wirbel J, Pyl PT, Kartal E, Zych K, Kashani A, Milanese A, et al. Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer. Nat Med. 2019;25:679–89.CrossRefGoogle Scholar
  66. 66.
    Byrne CS, Chambers ES, Morrison DJ, Frost G. The role of short chain fatty acids in appetite regulation and energy homeostasis. Int J Obes. 2015;39:1331.CrossRefGoogle Scholar
  67. 67.
    Jan G, Belzacq A, Haouzi D, Rouault A, Metivier D, Kroemer G, et al. Propionibacteria induce apoptosis of colorectal carcinoma cells via short-chain fatty acids acting on mitochondria. Cell Death Diff. 2002;9:179–88.CrossRefGoogle Scholar
  68. 68.
    Wei W, Sun W, Yu S, Yang Y, Ai L. Butyrate production from high-fiber diet protects against lymphoma tumor. Leuk Lymphoma. 2016;57:2401–8.CrossRefGoogle Scholar
  69. 69.
    Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly-Y M, et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science. 2013;341:569–73.CrossRefGoogle Scholar
  70. 70.
    Delmee E, Cani PD, Gual G, Knauf C, Burcelin R, Maton N, et al. Relation between colonic proglucagon expression and metabolic response to oligofructose in high fat diet-fed mice. Life Sci. 2006;79:1007–13.CrossRefGoogle Scholar
  71. 71.
    Wiemann B, Starnes CO. Coley’s toxins, tumor necrosis factor and cancer research: A historical perspective. Pharmacol Ther. 1994;64:529–64.CrossRefGoogle Scholar
  72. 72.
    Wu Y, Li RW, Huang H, Fletcher A, Yu L, Pham Q, et al. Inhibition of tumor growth by dietary indole-3-carbinol in a prostate cancer xenograft model may be associated with disrupted gut microbial interactions. Nutrients. 2019;11.  https://doi.org/10.3390/nu11020467.CrossRefGoogle Scholar
  73. 73.
    Turnbaugh PJ, Ridaura VK, Faith JJ, Rey FE, Knight R, Gordon JI. The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. Sci Transl Med. 2009;1:6ra14.CrossRefGoogle Scholar
  74. 74.
    Newton RU, Christophersen CT, Fairman CM, Hart NH, Taaffe DR, Broadhurst D, et al. Does exercise impact gut microbiota composition in men receiving androgen deprivation therapy for prostate cancer? A single-blinded, two-armed, randomised controlled trial. BMJ Open. 2019;9:e024872.CrossRefGoogle Scholar
  75. 75.
    Harada N, Hanaoka R, Horiuchi H, Kitakaze T, Mitani T, Inui H, et al. Castration influences intestinal microflora and induces abdominal obesity in high-fat diet-fed mice. Sci Rep. 2016;6:23001.CrossRefGoogle Scholar
  76. 76.
    Liu Y, Wu X, Jiang H. High dietary fat intake lowers serum equol concentration and promotes prostate carcinogenesis in a transgenic mouse prostate model. Nutr Metab (Lond). 2019;16:24–019-0351-x eCollection 2019.Google Scholar
  77. 77.
    • Sfanos KS, Markowski MC, Peiffer LB, Ernst SE, White JR, Pienta KJ, et al. Compositional differences in gastrointestinal microbiota in prostate cancer patients treated with androgen axis-targeted therapies. Prostate Cancer Prostatic Dis. 2018;21:539–48. This article address the microbiome in advanced prostate cancer in men on androgen deprivation. CrossRefGoogle Scholar
  78. 78.
    Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, et al. Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors. Science. 2018;359:91–7.CrossRefGoogle Scholar
  79. 79.
    Vetizou M, Pitt JM, Daillere R, Lepage P, Waldschmitt N, Flament C, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015;350:1079–84.CrossRefGoogle Scholar
  80. 80.
    Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, et al. Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients. Science. 2018;359:97–103.CrossRefGoogle Scholar
  81. 81.
    Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre ML, et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science. 2018;359:104–8.CrossRefGoogle Scholar
  82. 82.
    Helmink BA, Khan MAW, Hermann A, Gopalakrishnan V, Wargo JA. The microbiome, cancer, and cancer therapy. Nat Med. 2019;25:377–88.CrossRefGoogle Scholar
  83. 83.
    Hamada T, Nowak JA, Milner D Jr. A., M Song, S Ogino. Integration of microbiology, molecular pathology, and epidemiology: a new paradigm to explore the pathogenesis of microbiome-driven neoplasms. J Pathol. 2019;247:615–28.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of UrologyUniversity of Texas Health Science CenterSan AntonioUSA

Personalised recommendations